Blood
Articles in this Issue
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
Abstract Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell, targets and eliminates CD19/CD20-positive tumor cells. This phase 1, open-lab...
X-linked sideroblastic anemia in females
Abstract X-linked sideroblastic anemia (XLSA) in female carriers of 5-aminolevulinic acid synthase 2 mutations is not uncommon. We describe unique features and genotype/phenotype cor...
Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia
Abstract Although complete remission rates in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have improved over the last 2 decades, it is still inferior to that...
Introduction to a review series on acute lymphoblastic leukemia
Our understanding of the biology of acute lymphoblastic leukemia (ALL) continues to be refined, and these advances naturally lead to improvements in therapy and outcomes for pediatric and adult patien...
Progressive chromatin rewiring by ETO2::GLIS2 revealed in a genome-edited human iPSC model of pediatric leukemia initiation
Abstract Pediatric acute myeloid leukemia frequently harbors fusion oncogenes associated with poor prognosis, including KMT2A, NUP98, and GLIS2 rearrangements. Although murine models...
The immunotherapy real estate of Hodgkin lymphoma
The present and future of CAR T-cell therapy for adult B-cell ALL
Abstract Chimeric antigen receptor T-cell therapy (CAR-T) targeting CD19 has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), with...
Chromoplexy and <i>FNDC3B</i>::<i>RARB</i> fusion: deciphering a rare case of <i>PML</i>::<i>RARA</i>-negative APL
Giant cytoplasmic inclusions (Alder-Reilly bodies) in Hurler syndrome (mucopolysaccharidosis type 1H)
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Abstract Patients with relapsed/refractory diffuse large B-cell lymphoma progressing after chimeric antigen receptor T-cell (CAR-T) therapy have dismal outcomes. The prespecified pos...
Prizloncabtagene autoleucel: a new CAR T cell for B-NHL
Genetic subtypes of B-cell acute lymphoblastic leukemia in adults
Abstract B-cell acute lymphoblastic leukemia (B-ALL) is a rare malignancy in adults, with outcomes remaining poor, especially compared with children. Over the past 2 decades, extensi...
Classification and risk stratification in T-lineage acute lymphoblastic leukemia
Abstract Cure rates for patients with acute lymphoblastic leukemia (ALL) have improved markedly in recent decades, in part because of risk stratification incorporating leukemia genom...
Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma
Abstract The success of targeted therapies for hematological malignancies has heralded their potential as both salvage treatment and early treatment lines, reducing the need for high...
“When I’m 64”: functional shift of aging platelets
CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia
Abstract Recurrent isocitrate dehydrogenase (IDH) mutations catalyze nicotinamide adenine dinucleotide phosphate (NADPH)–dependent production of oncometabolite (R)-2-hydroxyglutarate...
Two strikes, base hit: odronextamab after CAR T cells in LBCL
iPSCs unlock clues to pediatric AML onset
Aging platelets shift their hemostatic properties to inflammatory functions
Abstract Platelets are crucial players in hemostasis and thrombosis but also contribute to immune regulation and host defense, using different receptors, signaling pathways, and effe...